Porous nanoparticles as delivery system of complex antigens for an effective vaccine against acute and chronic Toxoplasma gondii infection

Biomaterials

Volumn 50, Issue 1, 2015, Pages 164-175

  Dimier Poisson, Isabelle ^a,b   Carpentier, Rodolphe ^c,d   N'Guyen, Thi Thanh Loi ^a,b   Dahmani, Fatima ^c,d   Ducournau, Céline ^a,b   Betbeder, Didier ^c,d  

^a UNIVERSITÉ DE TOURS   (France)

^b UR1282   (France)

^c UNIVERSITÉ DE LILLE   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Immunotherapy; Nanoparticles; Nasal immunization; Toxoplasma gondii; Vaccine

Indexed keywords

ANTIGENS; MOBILE SECURITY; NANOPARTICLES;

CELLULAR ACTIVATION; DELIVERY SYSTEMS; IMMUNE MODULATORS; IMMUNOTHERAPY; POROUS NANOPARTICLES; PRO-INFLAMMATORY CYTOKINES; TOXOPLASMA GONDII; VACCINE DELIVERY;

VACCINES;

ALPHA INTERFERON; ANTIGEN; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; NANOPARTICLE; POROUS MALTODEXTRIN BASED WITH LIPID CORE NANOPARTICLE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOXOPLASMA GONDII ANTIGEN; TOXOPLASMA GONDII VACCINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; BOVINE SERUM ALBUMIN; PARASITE ANTIGEN; PROTOZOAL VACCINE; TOLL LIKE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ACTIVATION; CELL MATURATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; DRUG DELIVERY SYSTEM; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PARASITE LOAD; PARASITE SURVIVAL; PARTICLE SIZE; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; RESPIRATORY TRACT MUCOSA; SIGNAL TRANSDUCTION; TH1 CELL; TH17 CELL; TOXOPLASMOSIS; VACCINATION; ZETA POTENTIAL; ACUTE DISEASE; ANIMAL; CELL LINE; CHEMISTRY; CHRONIC DISEASE; CYTOLOGY; EPITHELIUM CELL; IMMUNOLOGY; IMMUNOMODULATION; INTRANASAL DRUG ADMINISTRATION; LEUKOCYTE; MACROPHAGE; METABOLISM; PARASITOLOGY; STATIC ELECTRICITY; TOXOPLASMA; ULTRASTRUCTURE;

TOXOPLASMA GONDII;

ACUTE DISEASE; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIGENS, PROTOZOAN; CELL LINE; CHRONIC DISEASE; DENDRITIC CELLS; EPITHELIAL CELLS; FEMALE; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNOMODULATION; LEUKOCYTES; MACROPHAGES; MICE; NANOPARTICLES; NF-KAPPA B; PARTICLE SIZE; PROTOZOAN VACCINES; RESPIRATORY MUCOSA; SERUM ALBUMIN, BOVINE; STATIC ELECTRICITY; TOLL-LIKE RECEPTORS; TOXOPLASMA; TOXOPLASMOSIS;

EID: 84932605834     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.01.056     Document Type: Article

References (43)

1. Pliaka V., Kyriakopoulou Z., Markoulatos P. Risks associated with the use of live-attenuated vaccine poliovirus strains and the strategies for control and eradication of paralytic poliomyelitis. Expert Rev Vaccines 2012, 11:609-628.
2. Azmi F., Ahmad Fuaad A.A., Skwarczynski M., Toth I. Recent progress in adjuvant discovery for peptide-based subunit vaccines. Hum Vaccines Immunother 2013, 10.
3. van Riet E., Ainai A., Suzuki T., Kersten G., Hasegawa H. Combatting infectious diseases; nanotechnology as a platform for rational vaccine design. Adv Drug Deliv Rev 74, 2014, 74:28-34.
4. Moon J.J., Suh H., Bershteyn A., Stephan M.T., Liu H., Huang B., et al. Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses. Nat Mater 2011, 10:243-251.
5. De Koker S., Lambrecht B.N., Willart M.A., van Kooyk Y., Grooten J., Vervaet C., et al. Designing polymeric particles for antigen delivery. Chem Soc Rev 2011, 40:320-339.
6. Reddy S.T., van der Vlies A.J., Simeoni E., Angeli V., Randolph G.J., O'Neil C.P., et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat Biotechnol 2007, 25:1159-1164.
7. Kwon Y.J., James E., Shastri N., Frechet J.M. Invivo targeting of dendritic cells for activation of cellular immunity using vaccine carriers based on pH-responsive microparticles. Proc Natl Acad Sci U S A 2005, 102:18264-18268.
8. Kasturi S.P., Skountzou I., Albrecht R.A., Koutsonanos D., Hua T., Nakaya H.I., et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 2011, 470:543-547.
9. Hill D., Dubey J.P. Toxoplasma gondii: transmission, diagnosis and prevention. Clin Microbiol Infect 2002, 8:634-640.
10. Toxoplasmosis: a comprehensive clinical guide 2001, 74. Cambridge University Press. D.H.M. Joynson, T.G. Wreghitt (Eds.).
11. Buxton D. Protozoan infections (Toxoplasma gondii, Neospora caninum and Sarcocystis spp.) in sheep and goats: recent advances. Veterinary Res 1998, 29:289-310.
12. Frenkel J.K. Pathophysiology of toxoplasmosis. Parasitol Today 1988, 4:273-278.
13. Denkers E.Y., Gazzinelli R.T. Regulation and function of T-cell mediated immunity during Toxoplasma gondii infection. Clin Microbiol Rev 1998, 11:569-588.
14. Gazzinelli R., Hakim F.T., Hieny S., Shearer G.M., Sher A. Synergistic role of CD4+ and CD8+ T lymphocytes in IFN-gamma production and protective immunity induced by an attenuated Toxoplasma gondii vaccine. JImmunol 1991, 146:286-292.
15. Gazzinelli R., Xu Y., Hieny S., Cheever A., Sher A. Simultaneous depletion of CD4+ and CD8+ T lymphocytes is required to reactivate chronic infection with Toxoplasma gondii. JImmunol 1992, 149:175-180.
16. Suzuki Y., Orellana M.A., Schreiber R.D., Remington J.S. Interferon-γ: the major mediator of resistance against Toxoplasma gondii. Science 1988, 240:516-518.
17. Suzuki Y., Remington J.S. Dual regulation of resistance against Toxoplasma gondii infection by Lyt-2+ and Lyt-1+, L3T4+ T cells in mice. JImmunol 1988, 140:3943-3946.
18. Shirahata T., Yamashita T., Ohta C., Goto H., Nakane A. CD8(+) T lymphocytes are the major cell population involved in the early gamma interferon response and resistance to acute primary Toxoplasma gondii infection in mice. Microbiol Immunol 1994, 38:789-796.
19. Khan I.A., Ely K.H., Kasper L.H. Antigen-specific CD8(+) T cell clone protects against acute Toxoplasma gondii infection in mice. JImmunol 1994, 152:1856-1860.
20. Casciotti L., Ely K.H., Williams M.E., Khan I.A. CD8+-T-cell immunity against Toxoplasma gondii can be induced but not maintained in mice lacking conventional CD4+ T cells. Infect Immun 2002, 70:434-443.
21. Lycke N. Recent progress in mucosal vaccine development: potential and limitations. Nat Rev Immunol 2012, 12:592-605.
22. Neutra M.R., Kozlowski P.A. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 2006, 6:148-158.
23. Bulow R., Boothroyd J.C. Protection of mice from fatal Toxoplasma gondii infection by immunization with p30 antigen in liposomes. JImmunol 1991, 147:3496-3500.
24. Hedhli D., Dimier-Poisson I., Judge J.W., Rosenberg B., Mévélec M.N. Protective immunity against Toxoplasma challenge in mice by coadministration of T.gondii antigens and Eimeria profilin-like protein as an adjuvant. Vaccine 2009, 27:2274-2281.
25. Grover H.S., Blanchard N., Gonzalez F., Chan S., Robey E.A., Shastri N. The Toxoplasma gondii peptide AS15 elicits CD4 T cells that can control parasite burden. Infect Immun 2012, 80:3279-3288.
26. Azegami T., Yuki Y., Kiyono H. Challenges in mucosal vaccines for the control of infectious diseases. Int Immunol 2014, 26:517-528.
27. Debard N., Buzoni-Gatel D., Bout D. Intranasal immunization with SAG1 protein of Toxoplasma gondii in association with cholera toxin dramatically reduces development of cerebral cysts after oral infection. Infect Immun 1996, 64:2158-2166.
28. Lycke N., Holmgren J. Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens. Immunology 1986, 59:301-308.
29. Elson C.O., Ealding W. Generalized systemic and mucosal immunity in mice after mucosal stimulation with cholera toxin. JImmunol 1984, 132:2736-2741.
30. Klippstein R., Pozo D. Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies. Nanomed Nanotechnol Biol Med 2010, 6:523-529.
31. Okamoto S., Matsuura M., Akagi T., Akashi M., Tanimoto T., Ishikawa T., et al. Poly(gamma-glutamic acid) nano-particles combined with mucosal influenza virus hemagglutinin vaccine protects against influenza virus infection in mice. Vaccine 2009, 27:5896-5905.
32. Caputo A., Castaldello A., Brocca-Cofano E., Voltan R., Bortolazzi F., Altavilla G., et al. Induction of humoral and enhanced cellular immune responses by novel core-shell nanosphere- and microsphere-based vaccine formulations following systemic and mucosal administration. Vaccine 2009, 27:3605-3615.
33. Debin A., Kravtzoff R., Santiago J.V., Cazales L., Sperandio S., Melber K., et al. Intranasal immunization with recombinant antigens associated with new cationic particles induces strong mucosal as well as systemic antibody and CTL responses. Vaccine 2002, 20:2752-2763.
34. Dombu C.Y., Betbeder D. Airway delivery of peptides and proteins using nanoparticles. Biomaterials 2013, 34:516-525.
35. Dombu C., Carpentier R., Betbeder D. Influence of surface charge and inner composition of nanoparticles on intracellular delivery of proteins in airway epithelial cells. Biomaterials 2012 Dec, 33(35):9117-9126. 10.1016/j.biomaterials.2012.08.064.
36. Ismael A.B., Sekkai D., Collin C., Bout D., Mevelec M.N. The MIC3 gene of Toxoplasma gondii is a novel potent vaccine candidate against toxoplasmosis. Infect Immun 2003, 71:6222-6228.
37. Paillard A., Passirani C., Saulnier P., Kroubi M., Garcion E., Benoit J.P., et al. Positively-charged, porous, polysaccharide nanoparticles loaded with anionic molecules behave as 'stealth' cationic nanocarriers. Pharm Res 2010, 27:126-133.
38. Mahony D., Cavallaro A.S., Mody K.T., Xiong L., Mahony T.J., Qiao S.Z., et al. Invivo delivery of bovine viral diahorrea virus, E2 protein using hollow mesoporous silica nanoparticles. Nanoscale 2014, 6:6617-6626.
39. Smith P.J., Giroud M., Wiggins H.L., Gower F., Thorley J.A., Stolpe B., et al. Cellular entry of nanoparticles via serum sensitive clathrin-mediated endocytosis, and plasma membrane permeabilization. Int J Nanomed 2012, 7:2045-2055.
40. Merhi M., Dombu C.Y., Brient A., Chang J., Platel A., Le Curieux F., et al. Study of serum interaction with a cationic nanoparticle: Implications for invitro endocytosis, cytotoxicity and genotoxicity. Int J Pharm 2012, 423:37-44.
41. Iwasaki A., Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004, 5:987-995.
42. Debierre-Grockiego F., Campos M.A., Azzouz N., Schmidt J., Bieker U., Resende M.G., et al. Activation of TLR2 and TLR4 by glycosylphosphatidylinositols derived from Toxoplasma gondii. JImmunol 2007, 179:1129-1137.
43. Aosai F., Rodriguez Pena M.S., Mun H.S., Fang H., Mitsunaga T., Norose K., et al. Toxoplasma gondii-derived heat shock protein 70 stimulates maturation of murine bone marrow-derived dendritic cells via Toll-like receptor 4. Cell Stress Chaperones 2006, 11:13-22.